Sepsis management and antiendotoxin therapy after nebacumab. A reappraisal, PMID: 7521827
Centoxin, PMID: 8435673
Marketed therapeutic antibodies compendium, PMID: 22531442
The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin, PMID: 22531443
Biotechnology and clinical trials, PMID: 11865440
Update on monoclonal antibody therapy in the gram-negative sepsis syndrome, PMID: 1429060
Antiendotoxin monoclonal antibodies. What future now?, PMID: 7848542
Assessment of biotechnology drugs: what are the issues?, PMID: 10538922
Monoclonal antibodies to endotoxin in the management of sepsis, PMID: 8317126
Issues in the adjunct therapy of severe sepsis, PMID: 8877531
Anti-endotoxin monoclonal antibodies, PMID: 1552929
Anti-endotoxin monoclonal antibodies, PMID: 1552919
Monoclonal antibody therapy for gram-negative sepsis: principles, applications, and controversies, PMID: 8469619
Looking back on HA-1A, PMID: 7979833
Advances in the therapy for sepsis in children, PMID: 9057790
Sepsis therapy still shocking, PMID: 9219250
P & T Committee response to evolving technologies: preparing for the launch of high-tech, high-cost products. Roundtable discussion, PMID: 10117768
Single-dose pharmacokinetics and safety of HA-1A, a human IgM anti-lipid-A monoclonal antibody, in pediatric patients with sepsis syndrome, PMID: 8501580
Antiendotoxin antibodies: a dead end?, PMID: 8198349
Anti-endotoxin monoclonal antibodies--a second look, PMID: 1552918
Economic assessment of drugs in Spain, PMID: 10146905
Management of generalized faecal peritonitis, PMID: 1294127
Perspectives for the future, PMID: 8227736
New treatments for sepsis, PMID: 8365201
[Immunotherapy in sepsis syndrome], PMID: 1603159
New drugs on the horizon, PMID: 1534032
The economics of gene therapy and of pharmacogenetics, PMID: 11873384
Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies, PMID: 1611812
The search for a magic bullet to fight sepsis, PMID: 8474207
Immunotherapy of sepsis, PMID: 8474114
Lessons learned from clinical trials on monoclonal anti-endotoxin antibody, PMID: 8203986
Management of pre-eclampsia, PMID: 8679381
New treatments for septic shock, PMID: 1741367
Monoclonal antiendotoxin agent HA-1A (Centoxin), PMID: 8093933
[Septomonab (Centoxin) in the treatment of gram-negative septicemia], PMID: 8497944
Anti-endotoxin therapy in primate bacteremia with HA-1A and BPI, PMID: 8024362
Thoughts on drug development, PMID: 1634635
Antiendotoxin therapy in sepsis, PMID: 8398040
[Introduction of immunotherapeutic agents in clinical practice; current status concerning anti-endotoxin antibody HA-1A in the control of sepsis], PMID: 8437630
Anatomy of an antibody, and related misadventures in developing an effective treatment for septic shock, PMID: 8361858
Challenges to the economic evaluation of new biotechnological interventions in healthcare, PMID: 10539393
HA-1A. A human monoclonal antibody for the treatment of gram-negative sepsis, PMID: 1578120
Clinical trials of immunotherapy for sepsis, PMID: 1597020
Human monoclonal antibodies in sepsis, PMID: 1791872
Anti-lipid A monoclonal antibody centoxin (HA-1A) binds to a wide variety of hydrophobic ligands, PMID: 9453659
Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide, PMID: 8418211
Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5, PMID: 8143464
Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients, PMID: 8417245
A controlled trial of HA-1A in a canine model of gram-negative septic shock, PMID: 8474201
Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels, PMID: 1431255
The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin., PMID:22531443
Marketed therapeutic antibodies compendium., PMID:22531442
The economics of gene therapy and of pharmacogenetics., PMID:11873384
Biotechnology and clinical trials., PMID:11865440
Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group., PMID:10825037
Challenges to the economic evaluation of new biotechnological interventions in healthcare., PMID:10539393
Assessment of biotechnology drugs: what are the issues?, PMID:10538922
Anti-lipid A monoclonal antibody centoxin (HA-1A) binds to a wide variety of hydrophobic ligands., PMID:9453659
Sepsis therapy still shocking., PMID:9219250
Influence of alterations in foregoing life-sustaining treatment practices on a clinical sepsis trial. The HA-1A Sepsis Study Group., PMID:9118650
Advances in the therapy for sepsis in children., PMID:9057790
Issues in the adjunct therapy of severe sepsis., PMID:8877531
Management of pre-eclampsia., PMID:8679381
The influence of clinical study design on cost-effectiveness projections for the treatment of gram-negative sepsis with human anti-endotoxin antibody., PMID:8924965
Anti-endotoxin human monoclonal antibody A6H4C5 (HA-1A) utilizes the VH4.21 gene., PMID:8845451
The relevance of searching for effects under a clinical-trial lamppost: a key issue., PMID:8544678
Effect of HA-1A monoclonal IgM antibody on endotoxin-induced proliferation of cultured rat middle ear epithelium., PMID:7872606
In vitro effects of HA-1A (Centoxin) on cytokine production in whole blood from intensive care unit patients., PMID:7880671
The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin., PMID:7979845
Looking back on HA-1A., PMID:7979833
Antiendotoxin monoclonal antibodies. What future now?, PMID:7848542
An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody., PMID:8045141
Antiendotoxin antibodies: a dead end?, PMID:8198349
Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group., PMID:8198341
Anti-endotoxin therapy in primate bacteremia with HA-1A and BPI., PMID:8024362
Projected impact of monoclonal anti-endotoxin antibody therapy., PMID:8203991
Lessons learned from clinical trials on monoclonal anti-endotoxin antibody., PMID:8203986
Sepsis management and antiendotoxin therapy after nebacumab. A reappraisal., PMID:7521827
HA-1A in septic patients with ARDS: results from the pivotal trial., PMID:7930026
The HA-1A saga: the scientific and ethical dilemma of innovative and costly therapies., PMID:7930023
Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5., PMID:8143464
Economic assessment of drugs in Spain., PMID:10146905
Cost-effectiveness of HA-1A treatment for patients with sepsis., PMID:7831376
[A cost-effectiveness analysis of treatment with antiendotoxin monoclonal antibodies in gram-negative sepsis]., PMID:8289526
[Is it possible to treat infections with non-antimicrobial agents?]., PMID:8142499
[Initial experience with monoclonal antibodies in therapy of life threatening nosocomial infections in the neonatal period]., PMID:8114779
New treatments for sepsis., PMID:8365201
Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin., PMID:8339592
Monoclonal antibodies, new technologies, and critical care medicine., PMID:8339573
Anatomy of an antibody, and related misadventures in developing an effective treatment for septic shock., PMID:8361858
Single-dose pharmacokinetics and safety of HA-1A, a human IgM anti-lipid-A monoclonal antibody, in pediatric patients with sepsis syndrome., PMID:8501580
Antiendotoxin therapy in sepsis., PMID:8398040
The search for a magic bullet to fight sepsis., PMID:8474207
A controlled trial of HA-1A in a canine model of gram-negative septic shock., PMID:8474201
Survival in selected patients with gram-negative sepsis after adjunctive therapy with HA-1A., PMID:8096292
Centoxin: the full story of its withdrawal., PMID:8490694
Centoxin: the full story of its withdrawal., PMID:8490693
[Septomonab (Centoxin) in the treatment of gram-negative septicemia]., PMID:8497944
[Preventive interruption of the administration of HA-1A monoclonal antibody against endotoxin]., PMID:8479241
Immunotherapy of sepsis., PMID:8474114
For research use only. Not for human or drug use.
